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was designed to assess efficacy and safety of teriflunomide, a novel oral disease
modifier, in RMS patients. The utility score, a measure of health-related quality of
life, was calculated via the EQ-5D questionnaire assessed alongside the trial. Using
baseline data, a cross-sectional analysis was performed to identify factors associ-
ated with utility scores using a multivariate regression linear model. This model
includes the following factors; expanded disability status scale (EDSS) score, type of
multiple sclerosis (relapsing remitting (RRMS) versus progressive relapsing (PRMS),
region, number or relapses within the past 2 years, previous MS medication, gen-
der, time (years) since first diagnosis of MS and burden of disease defined by mag-
netic resonance imaging. RESULTS: Three variables demonstrated a significant
negative impact on utility values: the functional disability level as assessed by
EDSS score (when EDSS score increases), PRMS versus RRMS and Eastern European
countries versus North American countries. The major influencing factor, consis-
tent with other analyses, was the EDSS score with the following disutility esti-
mates: EDSS[1-2[-0.021, p0.52; EDSS[2-3[-0.081, p0.0128; EDSS[3-4[-0.176,
p0.0001; EDSS[4-5[-0.237, p0.0001; EDSS[5-6[-0.231, p0.0001; EDSS[6-7[-
0.257, p0.0001]. In addition, disutilities associated with PRMS versus RRMS and
Eastern Europe region versus North American were respectively -0.073 (p0.0028)
and -0.038 (p0.0361). CONCLUSIONS: In RMS patients, these results confirm the
major impact of functional disability on patients’ utility. These analyses also pro-
vided disutility estimates per EDSS score, disutilities for PRMS versus RRMS and for
Eastern Europe versus North American region. The later probably reflecting cul-
tural differences in health status perception.
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OBJECTIVES: To examine resource utilization associated with the use of Rasagiline
or Selegiline, two commonly prescribed MAOB inhibitors for the treatment of Par-
kinson’s Disease (PD). METHODS: Data for this retrospective study were obtained
from the US i3 LabRx database over the time period from January 1, 2006 through
December 30, 2010. Patients were included in the analysis if they were prescribed
Rasagiline or Selegiline (with first such date identified as the index date), were
diagnosed with PD (ICD-9 code 332.0), and had continuous insurance coverage from
6 months prior through 12 months post index date. Analyses are primarily descrip-
tive in nature, with differences in categorical variables analyzed using chi-square
statistics and differences in continuous variables analyzed using t-statistics.
RESULTS: There were 1242 individuals included in the study - 926 initiated on
Rasagiline and 316 initiated on Selegiline. Patients initiated on Rasagiline, com-
pared to those intitiated on Selegiline, were significantly younger (63.2 years vs.
65.4 years; P0.0020). Patients initiated on Rasagiline were significantly less likely
to be diagnosed with chest pain (16.41% vs. 21.52%; P0.0402) or headaches (4.97%
vs. 9.49%; P0.0037). Patients who intitated on Rasagiline were significantly more
likely to visit a neurologist (93.63% vs. 89.24%; P0.0105). Compared with Selegiline
use, initiation on Rasagiline was associated with significantly fewer inpatient visits
(1.58 vs. 2.94; P0.0236) and significantly shorter hospital length of stay (4.71 days
vs. 8.78 days; P0.0216). CONCLUSIONS: Results from this retrospective study in-
dicate that, patients who initiated therapy with Selegiline, compared to Rasagiline
were more likely to experience side effects of chest pain or headaches. In addition,
these patients were more likely to have a greater resource utilization due to the
number and significantly longer lengths of hospitalizations.
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OBJECTIVES: This study aimed to identify the socioeconomic burden of HD in five
European countries METHODS: The survey was conducted in Germany, Italy,
France, Poland and the USA. The following patient data were collected: clinical
symptoms (motor, behavioral and psychiatric), functional/independence score,
QoL (H-QoLI, SF-36, EQ-5D), resource utilization, GP and specialist visits, other
healthcare professional visits, hospitalization, nursing home, social services, al-
lowance, medical device and daily out of pocket expenses. The following data were
collected from caregivers: time spent and working days lost caring for the patient,
out of pocket expenditure, caregiver quality of life. RESULTS: To date, 175, 124, 44,
60 and 134 patients were included in respectively France, Italy, Germany, Poland
and US. The populations were reasonably homogeneous regarding sociodemo-
graphic characteristics and severity such as age (48-56) and disease duration (6-10
years except for the Poland: 4 years). The average number of monthly visits to GP
was 0.76-1.32, to neurologist 0.49-1.12, to physiotherapist 0.09-5.59. The percentage
of patients admitted to hospital during the last 6 months was between 1% (USA)
and 19% (France). The mean ( SD) health utility (EQ-5D) ranged from 0.25 (0.46) in
France to 0.47 (0.37) in Germany. Caregivers spent between 6 (USA) and 22 hours/
day (Italy, Poland) caring for patients and their monthly expenses amounted to
€295 (Poland) to $2391 (USA). Caregivers also had reduced QoL. CONCLUSIONS: The
initial results indicated significant differences in access to health care and resource
use. France has the largest health care resource consumer by far. Countries that
use little health care resources compensate by a significantly larger caregiver in-
volvement. More data will be presented.
Neurological Disorders – Patient-Reported Outcomes & Preference-Based Studies
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OBJECTIVES: The impact of hereditary angioedema (HAE) on patients’ health re-
lated quality of life (QoL) extends beyond the acute attack period. This study was to
value the disutility of living with HAE outside of the acute attack period, according
to different emergency treatments available to the patient. METHODS: The study
used a vignette/health state scenario based approach and standard gamble meth-
odology. The health states described three different circumstances faced by pa-
tients with HAE in terms of availability of emergency medications should they
suffer a swelling attack: Scenario A: HAE without any effective emergency medi-
cation; Scenario B: HAE with effective emergency medication available in hospital;
Scenario C: HAE with effective emergency medication available for self-adminis-
tration. The health state descriptions were based evidence from on relevant clini-
cal trials, burden of disease and QoL studies and HAE treatment guidelines, sup-
ported by clinical expert opinion. The standard gamble survey was web based/
administered online. Respondents were recruited from an existing consumer
research panel. RESULTS: A total of 201 respondents completed the survey; 91%
were prepared to gamble with death to achieve perfect health in at least one of the
three health states. The mean utility weighting elicited for health state C was
significantly higher than either weightings elicited for health state B (0.75 [95%CI.
0.71, 0.79] versus 0.64 [95% CI 0.60, 0.69]; p0.001), or for health state A (0.75 [95%CI.
0.71, 0.79] versus 0.62 [95% CI 0.58, 0.67]; p0.001). There was no statistical differ-
ence between the utilities elicited for health states B and A. CONCLUSIONS: The
results demonstrate the recognition of and value placed on the QoL benefits pro-
vided by the availability of and immediate access to a self-administered emergency
medication for HAE over that provided by treatment available only in the hospital
accident and emergency treatment setting.
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OBJECTIVES: Health state utility values are the metric preferred by health care
decision makers to examine the relative value of various treatments to treat mi-
graine, including those that reduce the severity of migraine pain. This cross-sec-
tional, observational study aimed to estimate utility values for different levels of
migraine pain severity.METHODS:One hundred six participants from the UK (UK),
diagnosed with migraine, completed the EQ-5D™ to evaluate their health status for
mild, moderate, and severe levels of migraine pain severity for a recent migraine
attack and for current health (without migraine) defined as health status within 7
days post-attack, with no residual migraine symptoms. T-tests were used to com-
pare mean utility values between each level of severity to evaluate whether there
were significant differences in mean utility scores by migraine severity; Wilcoxon
signed rank test was also performed. RESULTS: Utility scores for each health state
were found to be significantly different from perfect health (p0.0001) and one
another (p0.0001). As severity worsened, utility decreased and the lowest mean
utility, -0.20 (95% confidence interval [CI]: -0.27-0.13), was for severe migraine
pain. Compared to current health (without migraine), utility decrements were 0.21,
0.34, and 1.07 for mild, moderate, and severe migraine pain states respectively. The
smallest difference in mean utility scores was between mild and moderate mi-
graine pain (0.13) and the largest difference in mean utility scores was between
current health (without migraine) and severe migraine pain (1.07). CONCLUSIONS:
Migraine pain severity was associated with significantly lower utility compared
with perfect health, with higher levels of pain severity associated with lower utility.
Severe migraine pain was considered a health state worse than death. Our results
can be used in cost-utility models examining the relative economic value of ther-
apeutic strategies for migraine in the UK.
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OBJECTIVES: H-QoL-I is a quality-of-life indicator specific to the Huntington’s Dis-
ease (HD), with 3 dimensions: motor function, psychology and socializing. It has
been validated in several countries (France, Italy, Poland, Germany and United
States). We compared several methods for mapping H-QoL-I onto EQ-5D and thus
derive utility values from H-QoL-I.METHODS: This analysis was based on a sample
of 315 HD patients who participated in an international survey on the burden of HD,
and completed H-QoL-I and EQ-5D, with help from caregivers if necessary. EQ-5D
index scores were calculated based on UK time trade-off tariff. The sample was
divided into 70% derivation and 30% validation sets. We compared three methods
to estimate patient’s utility as a function of 11 H-QoL-I items: ordinary least-
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squares (OLS) regression and Tobit regression, with utility score as independent
variable, and ordered logistic regression for each item of EQ-5D. Model perfor-
mance was assessed by comparing predicted and observed mean EQ-5D scores in
the validation set, the unadjusted R-squared and the root mean squared error
(RMSE). RESULTS: The OLS regression had the best predictive performance with
R-squared equal to 0.60 and RMSE equal to 0.25. The linear regression model accu-
rately estimated the mean EQ-5D score in the validation set (predicted score 0.32
versus observed score 0.30). RMSE values of 0.26 and 0.31 were obtained with Tobit
model and ordered logistic model. Items with the greatest contribution to variance
in the OLS model were ‘difficulty of tie the laces of my shoes’ (p0.0018), ‘difficulty
to drink without spilling’ (p0.0156) and ‘difficulty to make precise movements’
(p0.0165). CONCLUSIONS: EQ-5D utility scores can be reasonably predicted from
the H-QoL-I, although item wordings are not directly related. The model based on
OLS regression provides the best fitting. Motor functions items contributed the
model to utility predictions.
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POPULATION WITH A RELAPSING FORM OF MULTIPLE SCLEROSIS (RMS) USING
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OBJECTIVES: In patients with RMS, assess the impact of relapse(s) leading to hos-
pitalization on Health-Related Quality of Life (HR-QoL), fatigue and Health Care
resource utilisation. METHODS: TEMSO (N1088) was designed to assess efficacy
and safety of teriflunomide, a novel oral disease modifier, in RMS patients. Patients
with no relapse, patients with relapse(s) not leading to hospitalisation and patients
with at least one relapse leading to hospitalisation were analysed. The following
patient reported outcomes (PROs) were assessed; utility (EQ5D), PCS and MCS
(Physical and Mental Health Component Summaries) scores of the SF-36, fatigue
(FIS-total score). Also, Emergency Medical Facility Visits (EMFV; a visit to a medical
facility/hospital for emergency care not resulting in an admission) was tracked.
Changes from Baseline for PROs and annual EMFV rate were analysed for a two-
year period. RESULTS: Change from baseline (CfB) in utility in patients with no
relapse was 0.034, CfB in utility in patients with relapse(s) not leading to hospi-
talisation was -0.019(*p10.01) and CfB in utility in patients with relapse(s) leading
to hospitalisation was -0.057(p10.001; p2:ns). Similar results were seen for PCS of
1.0, -1.0 (p10.01) and -3.1(p10.001; p20.05) respectively and for MCS were
respectively 1.8, -1.0(p10.01) and -2.7 (p10.001; p2:ns). This same trend was
observed with FIS total score, (CfB was respectively: -3.0, 1.4 (p1:ns) and 10.3
(p10.001; p20.01). The mean annual EMFV rate in patients with no relapse was
0.5 and in patients with relapse not leading to hospitalisation was 0.4 (p1:ns). This
rate was increased to 1.2 (p10.05; p20.001) in patients with relapse leading to
hospitalisation. CONCLUSIONS: In TEMSO, patients with relapse leading to hospi-
talisation comparatively have worsening in HR-QoL (EQ-5D, SF-36), fatigue and
have a higher number of EMFV. *p1: versus patients with no relapse, p2: versus
patients with relapse not leading to hospitalisation.
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OBJECTIVES: The original SAT is a five-item questionnaire developed to assess
treatment benefits associated with application of QUTENZA™, a novel high-dose
capsaicin patch, in clinical trials among patients with neuropathic pain . The ob-
jective of this study was to evaluate the item performance and psychometric prop-
erties of the SAT. METHODS: The SAT, Numerical Pain Rating Scale (NPRS), SF-36,
Brief Pain Inventory and Patient Global Impression of Change (PGCI) scores were
measured in two 12 week Phase3 clinical trials. Descriptive statistics, exploratory
and confirmatory factor analysis (EFA and CFE) were conducted to assess the item
performance and to explore the underlying constructs. Reliability and validity were
also examined. RESULTS: Pooled data from 698 patients (21-91 years) completing
SAT after 12 weeks of treatment were analyzed. From descriptive statistics, EFA
and CFA results, a one-factor model combining 4 of the 5 items emerged as the
optimal solution with 66% explained variance. The internal consistency reliability
was high (Cronbach’s alpha  0.87). Construct validity was demonstrated by mod-
erate to high correlations with change in the NPRS (-0.55 pain now and -0.64 aver-
age pain), BPI (-0.59 worst pain, -0.35 activity limitation), SF 36v2 pain subscale
(0.43) and PGIC (0.85). SAT scores strongly discriminated patient change groups
using the PGIC; mean SAT scores were 1.7 in patients who were very much im-
proved versus -1.0 in patients who were much worse/very much worse.
CONCLUSIONS: Preliminary analyses indicate that the measurement properties of
the four-item version of SAT are valid and reliable for patients self assessment of
treatment with QUTENZA™ among patients with neuropathic pain. The item per-
formance suggests that the questionnaire could be further improved with addi-
tional patient input to clarify some of the questions as well as revising the response
options and recall period to better reflect treatment benefits during the course of a
trial.
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OBJECTIVES: The original 40-question Fabry-specific Paediatric Health and Pain
Questionnaire (FPHPQ) was developed to understand and assess the symptoms in
Fabry Disease (FD) patients as no validated instrument existed. The objective of
this study was to evaluate the psychometric properties of the FPHPQ. METHODS:
FPHPQ data were collected from the FOS, a registry sponsored by Shire HGT for
patients with FD who were treatment naive or receiving enzyme replacement ther-
apy with agalsidase alfa. Descriptive statistics and exploratory factor analysis were
conducted to assess the item performance and to explore the underlying con-
structs. Reliability, validity, and responsiveness were also examined. RESULTS:
Eighty-seven children (aged 4-18 years) from 8 different countries completed the
questionnaire. From descriptive statistics and EFA, 23 items in three subscales
emerged: Pain associated with heat or exertion; pain associated with cold; abdom-
inal pain and fatigue. Internal consistency reliability for all three subscales was
good (Cronbach alpha  0.84) and high for all age groups (4-7, 8-12, 13-18 years).
Test-retest reliability was high for all three subscales (intraclass correlation coef-
ficient  0.74). Construct validity was demonstrated by moderate correlation with
the Brief Pain Inventory (BPI), KINDL, and EQ-5D. Known group validity showed that
all subscales were able to discriminate between mild and moderate FD severity as
classified by the FOS MSSI (Mainz Severity Score Index). The FPHPQ heat and exer-
tion subscale was responsive to change in symptoms between responders and
non-responders as defined by change in EQ-5D index scores between Visits 1 and 2.
CONCLUSIONS: Preliminary analyses indicate that the measurement properties of
FPHPQ are valid and reliable for assessing patient-reported symptoms of FD. The
questionnaire could be a useful tool for clinicians to understand the progression of
disease and monitor treatment effects. FPHPQ will be further validated and refined
as the FOS database is continuously adding more patients.
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DEVELOPMENT AND VALIDATION OF THE MULTIPLE SCLEROSIS RATING
SCALE-REVISED (MSRS-R)
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OBJECTIVES: PatientsLikeMe is an online health-data sharing community and re-
search platform for patients with chronic and life-changing health conditions. In
developing the PatientsLikeMe online platform for patients with Multiple Sclerosis
(MS), we required a patient-reported, multi-dimensional assessment of functional
status that was easy to complete. Existing measures of functional status were
inadequate; clinician-reported, focused on walking, and burdensome to complete.
To develop a longitudinal record accessible to patients using the site, we developed
the Multiple Sclerosis Rating Scale (MSRS). METHODS: We adapted a clinician-
rated measure, the Guy’s Neurological Disability Scale, to a self-report scale and
deployed it to an online community. As part of our validation process, we reviewed
online forum discussions between patients, conducted in-person patient cognitive
debriefing, and made minor improvements to form a revised scale (MSRS-R). The
MSRS-R was deployed as a cross-sectional survey to 4382 patients with relapsing-
remitting MS (RRMS) on the PatientsLikeMe platform. The survey included the
MSRS-R as well as a range of comparator MS measures: PRIMUS, MSIS-29, PDDS,
NARCOMS Performance Scales, and MSWS-12. RESULTS: In total, 816 RRMS pa-
tients responded. The MSRS-R exhibited high internal consistency (Cronbach’s
alpha 0.86) and 1-week retest reliability (r 0.91). The MSRS-R walking item was
highly correlated with alternative walking measures (PDDS, r 0.84; MSWS-12, r
0.83; NARCOMS mobility question, r 0.86). The MSRS-R correlated well with com-
parison instruments, and reliably differentiated between participants by PDDS dis-
ease stage, relapse severity, and time since diagnosis. Retrospective scoring of
most recent relapse suggested a 3-point increase in MSRS-R might usefully identify
relapses. CONCLUSIONS: The MSRS-R is a concise, multi-faceted measure of MS-
related functional disability. It may be useful for describing the impact of MS and
can support further inquiry into the factors that relate to variation in outcomes
among MS patients.
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OBJECTIVES: The Huntington Quality of Life Instrument (H-QoL-I) is a first self-
reported specific Health-Related Quality of Life (HR-QoL) instrument developed to
assess the QoL of patients suffering from Huntington’s disease. It was originally
developed and validated in French and in Italian. The instrument is being validated
in 11 languages. This study aims to validate the German, Polish and US versions of
H-QoL-I cross-culturally. METHODS: The original questionnaire was based on 11
items and 3 dimensions. The instrument was translated forwards and backwards
by native speakers. It was then reviewed and adjusted by local clinicians and tested
for face validity. A survey was conducted with 134 US, 60 Polish and 41 German
patients. Face validity was tested through item completion and overall under-
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